Table 2.
Studies investigating apremilast in palmoplantar pustulosis (PPP)
| Author, year, study name, study type | Comparison | Number of patients | PPPASI 50 (%) | PPPGA 0 or 1 (%) (baseline PPPGA ≥ 3) | Secondary outcomes |
|---|---|---|---|---|---|
|
Amgen 2022 [17] RCT |
Apremilast vs. placebo | 90 (86 with baseline PPPGA ≥ 3) | 78.3 vs. 40.9 (APR vs. PBO) (week 16) [P = 0.0003] |
Mean PPPASI improvement (%): 64.3 vs. 42.3 (APR vs. PBO) (week 16) PGA 0 or 1 (%): 19.6 vs. 4.5 (APR vs. PBO) (week 16) |
|
|
Reich et al. 2021 [18] APLANTUS Phase II clinical trial |
None | 21 (19 with baseline H&F PGA ≥ 3) | 33.3, 57.1, and 61.9 (weeks 4, 12 and 20) |
Median PPPASI improvement (%): 57.1 (week 20) [P = < 0.001] PPPASI 75 (%): 9.5, 28.6, and 14.3 (weeks 4, 12, and 20) Median DLQI improvement (%): 76.5 (week 20) [P = 0.03] |
|
|
Kato et al. 2021 [21] Retrospective cohort |
None | 10 | 80.0 (week 16) |
Mean PPPASI improvement (%): 61.9 (2 ± 1 weeks) [P = 0.013] PPPASI 75 (%): 50.0 (week 16) Mean DLQI improvement (%): 66.0 (2 ± 1 weeks) [P = 0.009] |
|
|
Kromer et al. 2019 [25] Retrospective cohort |
APR vs. cyclosporine vs. acitretin-PUVA vs. MTX vs. acitretin vs. alitretinoin vs. fumaric acid esters vs. certolizumab pegol vs. infliximab vs. golimumab vs. ustekinumab vs. adalimumab vs. secukinumab vs. etanercept) | 347 (35 treated with APR) |
Median drug survival (months): 15 vs. 12 vs. 9 vs. 8 vs. 6 vs. 5 vs. 3 vs. 47.4 vs. 26 vs. 22 vs. 21 vs. 18 vs. 9 vs. 8 (APR vs. cyclosporine vs. acitretin-PUVA vs. MTX vs. acitretin vs. alitretinoin vs. fumaric acid esters vs. certolizumab pegol vs. infliximab vs. golimumab vs. ustekinumab vs. adalimumab vs. secukinumab vs. etanercept) PPPASI 75 (%): 31.4 (APR) |
||
|
Kt et al. 2021 [28] Case Series |
None | 5 | 80.0 (average treatment duration 15.2 weeks) |
Mean PPPASI improvement (%): 72.9 (average treatment duration 15.2 weeks) PPPASI 75 (%): 40.0 (average treatment duration 15.2 weeks) |
APR apremilast, DLQI Dermatology Quality of Life Index, MTX methotrexate, PBO placebo, PGA physician global assessment, PPPASI Palmoplantar Pustulosis Area and Severity Index, PPPGA palmoplantar physician global assessment, PUVA psoralen plus ultraviolet A, RCT randomized controlled trial